20.08 08:27 | dpa-AFX: GSK :GSK5764227 Gets FDA Breakthrough Therapy Designation For Extensive-stage Small-cell Lung Cancer |
20.08 08:06 | dpa-AFX: *GSK GETS US FDA BREAKTHROUGH THERAPY DESIGNATION FOR GSK5764227 IN R/R EXTENSIVE-STAGE SMALL-CELL LUNG CANCER |
20.08 08:03 | dpa-AFX: *GSK RECEIVES US FDA BREAKTHROUGH THERAPY DESIGNATION FOR GSK5764227 IN R/R EXTENSIVE-STAGE SMALL-CELL LUNG CANCER |
16.08 13:25 | dpa-AFX: ANALYSE-FLASH: Goldman belässt GSK auf 'Neutral' - Ziel 1850 Pence |
16.08 13:25 | dpa-AFX: Goldman belässt GSK auf 'Neutral' - Ziel 1850 Pence |
16.08 10:02 | GSK gewinnt in Florida Rechtsstreit zu Zantac-Krebsvorwurf |
16.08 09:00 | dpa-AFX: GSK To Seek Dismissal Of Wilson Case In Florida After Favorable Daubert Ruling |
16.08 08:05 | dpa-AFX: *GSK PLC WELCOMES DAUBERT RULING BY THE FLORIDA STATE COURT |
15.08 10:58 | dpa-AFX: ANALYSE-FLASH: Berenberg belässt GSK auf 'Buy' - Ziel 1820 Pence |
15.08 10:58 | dpa-AFX: Berenberg belässt GSK auf 'Buy' - Ziel 1820 Pence |
06.08 08:12 | dpa-AFX: *JURY IN JOINER CASE IN ILLINOIS STATE COURT FINDS GSK NOT LIABLE FOR PLAINTIFF'S COLORECTAL CANCER |
06.08 08:02 | dpa-AFX: *JURY IN JOINER CASE IN ILLINOIS STATE COURT FINDS GSK NOT LIABLE FOR PLAINTIFF'S COLORECTAL CANCER |
02.08 10:48 | dpa-AFX: Goldman belässt GSK auf 'Neutral' - Ziel 1850 Pence |
02.08 09:49 | dpa-AFX: ANALYSE-FLASH: JPMorgan senkt Ziel für GSK auf 1550 Pence - 'Underweight' |
02.08 09:49 | dpa-AFX: JPMorgan senkt Ziel für GSK auf 1550 Pence - 'Underweight' |
02.08 09:36 | dpa-AFX: *STIFEL RAISES GSK PRICE TARGET TO 1770 (1740) PENCE - 'HOLD' |
02.08 08:14 | dpa-AFX: GSK Reports Expanded Approval For Jemperli Plus Chemotherapy |
02.08 08:06 | dpa-AFX: *GSK: FDA EXPANDS JEMPERLI + CHEMOTHERAPY APPROVAL FOR ADULTS WITH PRIMARY ADVANCED OR RECURRENT ENDOMETRIAL CANCER |
02.08 08:04 | dpa-AFX: *GSK'S JEMPERLI RECEIVES FDA APPROVAL FOR ADVANCED ENDOMETRIAL CANCER IN COMBINATION WITH CHEMOTHERAPY |
02.08 06:12 | dpa-AFX: *JPMORGAN SENKT ZIEL FÜR GSK AUF 1550 (1660) PENCE - 'UNDERWEIGHT' |
|